Agios Pharmaceuticals, Inc.
DE ˙ DB ˙ US00847X1046
23,40 € ↑0,80 (3,54%)
2026-06-04
AKTIENPREIS
SecurityDE:8AP / Agios Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership967,525 shares
Latest Disclosed Value $ 32,731,410
Morgan Stanley reports 8.22% increase in ownership of 8AP / Agios Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 967,525 shares of Agios Pharmaceuticals, Inc. (DE:8AP) valued at $24,962,145 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 894,037 shares of Agios Pharmaceuticals, Inc.. This represents a change in shares of 8.22% during the quarter. The current value of the position is $22,640,085 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 967,525 73,488 8.22 32,731 34.50 0.0020
2026-05-27 2025-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 894,037 477,039 114.40 24,336 45.39 0.0015
2026-02-13 2025-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 894,037 477,039 24,336 0.0015
2026-05-27 2025-09-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 416,998 125,033 42.82 16,738 72.38 0.0010
2025-11-14 2025-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 416,998 125,033 16,738 0.0010
2025-08-15 2025-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 291,965 -2,658 -0.90 9,711 12.49 0.0006
2025-05-15 2025-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 294,623 -83,466 -22.08 8,632 -30.52 0.0006
2025-05-15 2024-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 378,089 29,116 8.34 12,424 -19.87 0.0009
2025-02-14 2024-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 378,089 29,116 12,424 0.0009
2025-05-14 2024-09-30 13F/A-2 AGIOS PHARMACEUTICALS COM 00847X104 348,973 -247,702 -41.51 15,505 -39.74 0.0011
2025-02-14 2024-09-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 348,973 -247,702 15,505 0.0011
2024-11-14 2024-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 348,973 -247,702 15,505 0.0001
2025-05-14 2024-06-30 13F/A-2 AGIOS PHARMACEUTICALS COM 00847X104 596,675 -583,651 -49.45 25,729 -25.45 0.0020
2024-10-17 2024-06-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 596,675 -583,651 25,729 0.0020
2024-08-14 2024-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 596,675 -583,651 25,729 0.0020
2024-10-17 2024-03-31 13F/A-2 AGIOS PHARMACEUTICALS COM 00847X104 1,180,326 686,739 139.13 34,513 213.97 0.0028
2024-08-16 2024-03-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 1,180,326 686,739 34,513 0.0003
2024-05-15 2024-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 1,180,326 686,739 34,513 0.0028
2024-08-16 2023-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 493,587 119,458 31.93 10,992 18.72 0.0010
2024-02-13 2023-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 493,587 119,458 10,992 0.0010
2023-11-15 2023-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 374,129 -17,338 -4.43 9,260 -16.48 0.0009
2023-08-14 2023-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 391,467 80,685 25.96 11,086 55.31 0.0011
2023-05-15 2023-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 310,782 -55,737 -15.21 7,139 -30.64 0.0008
2023-02-14 2022-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 366,519 86,988 31.12 10,292 30.15 0.0012
2022-11-14 2022-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 279,531 -136,605 -32.83 7,907 -14.29 0.0011
2022-10-27 2022-06-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 416,136 85,605 25.90 9,225 -4.13 0.0012
2022-08-15 2022-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 416,136 85,605 9,225 0.0002
2022-10-27 2022-03-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 330,531 72,595 28.14 9,622 13.51 0.0013
2022-05-13 2022-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 330,531 72,595 9,622 0.0013
2022-02-14 2021-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 257,936 81,643 46.31 8,477 4.19 0.0010
2021-11-15 2021-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 176,293 -108,475 -38.09 8,136 -48.16 0.0011
2021-08-23 2021-06-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 284,768 -79,626 -21.85 15,693 -16.60 0.0021
2021-08-16 2021-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 284,768 -79,626 15,693 0.0004
2021-05-17 2021-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 364,394 142,214 64.01 18,817 95.46 0.0028
2021-02-16 2020-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 222,180 -221,528 -49.93 9,627 -38.02 0.0015
2020-11-13 2020-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 443,708 393,452 782.90 15,532 478.04 0.0030
2020-08-14 2020-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 50,256 -72,128 -58.94 2,687 -38.12 0.0006
2020-05-26 2020-03-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 122,384 -31,285 -20.36 4,342 -40.83 0.0012
2020-05-15 2020-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 122,384 -31,285 4,342 333.5561
2020-02-14 2019-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 153,669 130,680 568.45 7,338 886.29 0.0017
2019-11-14 2019-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 22,989 -56,567 -71.10 744 -81.25 0.0002
2019-08-14 2019-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 79,556 21,107 36.11 3,967 0.63 0.0011
2019-05-15 2019-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 58,449 -20,237 -25.72 3,942 8.65 0.0011
2019-02-14 2018-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 78,686 28,737 57.53 3,628 -5.84 0.0011
2019-04-23 2018-09-30 13F/A-2 AGIOS PHARMACEUTICALS COM 00847X104 49,949 -39,251 -44.00 3,853 -48.72 0.0010
2018-11-20 2018-09-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 49,949 0 3,853 0.0010
2018-11-14 2018-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 49,949 -39,251 3,853
2019-04-23 2018-06-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 89,200 20,827 30.46 7,514 34.37 0.0020
2018-08-14 2018-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 89,200 20,827 7,514
2019-04-23 2018-03-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 68,373 13,534 24.68 5,592 78.37 0.0016
2018-05-14 2018-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 68,373 13,534 5,592
2019-04-23 2017-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 54,839 -48,073 -46.71 3,135 -54.36 0.0009
2018-02-14 2017-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 54,839 -48,073 3,135
2017-11-14 2017-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 102,912 26,737 35.10 6,869 75.27 0.0021
2017-08-11 2017-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 76,175 11,840 18.40 3,919 4.34 0.0012
2017-05-22 2017-03-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 64,335 -19,537 -23.29 3,756 7.34 0.0012
2017-05-12 2017-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 64,335 3,756
2017-02-22 2016-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 83,872 -14,211 -14.49 3,499 -32.46 0.0011
2017-02-13 2016-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 83,872 3,499
2016-11-10 2016-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 98,083 -8,821 -8.25 5,181 15.67 0.0018
2016-08-12 2016-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 106,904 -12,626 -10.56 4,479 -7.71 0.0016
2016-05-12 2016-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 119,530 -20,003 -14.34 4,853 -46.42 0.0019
2016-02-09 2015-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 139,533 -1,107 -0.79 9,058 -8.76 0.0033
2016-02-08 2015-09-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 140,640 -26,136 -15.67 9,928 -46.44 0.0037
2015-11-09 2015-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 140,640 9,928
2015-08-12 2015-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 166,776 -21,165 -11.26 18,536 4.58 0.0064
2015-05-14 2015-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 187,941 -43,295 -18.72 17,724 -31.59 0.0065
2015-02-13 2014-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 231,236 20,927 9.95 25,908 100.79 0.0095
2014-12-16 2014-09-30 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 210,309 -1,215 -0.57 12,903 33.12 0.0050
2014-11-14 2014-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 210,309 12,903
2014-08-12 2014-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 211,524 10,023 4.97 9,693 22.85 0.0166
2014-05-13 2014-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 201,501 5,302 2.70 7,890 67.91 0.0033
2014-02-13 2013-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 196,199 -86,708 -30.65 4,699 -40.59 0.0020
2013-11-13 2013-09-30 13F AGIOS PHARMA COM 00847X104 282,907 282,907 7,910 0.0037
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.